The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients

Shang-Gin Wu; Yi-Nan Liu; Meng-Feng Tsai; Yih-Leong Chang; Chong-Jen Yu; Pan-Chyr Yang; James Chih-Hsin Yang; Yueh-Feng Wen; Jin-Yuan Shih

doi:10.18632/oncotarget.7189

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients

Oncotarget ◽

10.18632/oncotarget.7189 ◽

2016 ◽

Vol 7 (11) ◽

pp. 12404-12413 ◽

Cited By ~ 115

Author(s):

Shang-Gin Wu ◽

Yi-Nan Liu ◽

Meng-Feng Tsai ◽

Yih-Leong Chang ◽

Chong-Jen Yu ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Case Medical Research ◽

10.31525/ct1-nct04007835 ◽

2019 ◽

Author(s):

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Advanced Nsclc ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Nsclc Patients ◽

Egfr Tki

Download Full-text

Abstract 1756: Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma

10.1158/1538-7445.am2014-1756 ◽

2014 ◽

Author(s):

Hui-Yi Shiao ◽

Tsu-An Hsu ◽

Wen-Hsing Lin ◽

Tsong-Toh Yang ◽

Hui-Fang Hsieh ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma

BMC Cancer ◽

10.1186/s12885-018-5116-9 ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 1

Author(s):

Eun Young Kim ◽

Arum Kim ◽

Gaeun Lee ◽

Hangsuck Lee ◽

Yoon Soo Chang

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling

Breast Cancer Research and Treatment ◽

10.1007/s10549-007-9830-2 ◽

2007 ◽

Vol 112 (1) ◽

pp. 25-33 ◽

Cited By ~ 27

Author(s):

Nicola Normanno ◽

Manuela Campiglio ◽

Monica R. Maiello ◽

Antonella De Luca ◽

Mario Mancino ◽

...

Keyword(s):

Breast Cancer ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Cancer Cells ◽

Breast Cancer Cells ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Mapk Signaling ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma

Translational Lung Cancer Research ◽

10.21037/tlcr-20-893 ◽

2021 ◽

Vol 10 (2) ◽

pp. 699-711

Author(s):

Minsu Kang ◽

Changhee Park ◽

Se Hyun Kim ◽

Sock Won Yoon ◽

Koung Jin Suh ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Expression Level ◽

Egfr Tyrosine Kinase Inhibitor ◽

Programmed Death Ligand 1 ◽

Egfr Tyrosine Kinase ◽

Programmed Death

Download Full-text

Epigenetic Reprogramming Driven By Metabolic Alterations As A Mechanism Of EGFR – Tyrosine Kinase Inhibitor Resistance In Human Lung Adenocarcinoma

The FASEB Journal ◽

10.1096/fasebj.2020.34.s1.00602 ◽

2020 ◽

Vol 34 (S1) ◽

pp. 1-1

Author(s):

Abhilash Venugopalan ◽

Khoa Nguyen ◽

Matthew Lynberg ◽

Tapan Maity ◽

Yue Qi ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Human Lung ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Metabolic Alterations ◽

Human Lung Adenocarcinoma ◽

Egfr Tyrosine Kinase ◽

Inhibitor Resistance

Download Full-text

Predictive value of serum HGF for treatment response to EGFR tyrosine kinase inhibitor in patients with lung adenocarcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7563 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7563-7563

Author(s):

K. Kasahara ◽

T. Arao ◽

K. Sakai ◽

A. Sakai ◽

T. Sone ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Treatment Response ◽

Predictive Value ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Acquired resistance to EGFR tyrosine kinase inhibitor in A431 squamous cell carcinoma xenografts is mediated by c-Kit pathway transduction

Tumor Biology ◽

10.1007/s13277-014-2932-7 ◽

2014 ◽

Vol 36 (4) ◽

pp. 2993-2999 ◽

Cited By ~ 3

Author(s):

Lixia Zhang ◽

Xiaokun Yang ◽

Bei Zhao ◽

Zhen Cai

Keyword(s):

Squamous Cell Carcinoma ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Cell Carcinoma ◽

Squamous Cell ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR mutations

Molecular and Clinical Oncology ◽

10.3892/mco.2018.1550 ◽

2018 ◽

Author(s):

Ming‑Szu Hung ◽

Yu‑Hung Fang ◽

Yu‑Ching Lin ◽

Jr‑Hau Lung ◽

Meng‑Jer Hsieh ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Associated Factors ◽

Kinase Inhibitor ◽

Egfr Mutations ◽

First Line ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Download Full-text

Correlation between Efficacy of the EGFR Tyrosine Kinase Inhibitor and Serum Tumor Markers in Lung Adenocarcinoma Patients

Clinical Laboratory ◽

10.7754/clin.lab.2013.131002 ◽

2014 ◽

Vol 60 (09/2014) ◽

Cited By ~ 1

Author(s):

Jin Pan ◽

Yu Hou ◽

Guo Zhang

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitor ◽

Tumor Markers ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase Inhibitor ◽

Serum Tumor Markers ◽

Egfr Tyrosine Kinase

Download Full-text